Active surveillance (AS) has been claimed to avoid overtreatment of prostate cancer (PCa). It remains unclear which patients may benefit from AS. One way to clarify this is to improve the definition of insignificant PCa.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
PSA and Gleason score-the basic instruments used to select patients for AS-suffer from systematic errors. The nomograms used to define insignificant PCa are based on patients whose disease was classified before changes were introduced in the 2005 Consensus Conference on Gleason Grading; thus, the experience obtained cannot be directly applied to today's patients. Additionally, despite the standardization of prostate-specific antigen assays promoted by the World Health Organization, differences persist and could lead to misclassification of patients. These factors lead to an incorrect classification of patients into risk groups. Although new variables would increase risk group classification, the necessary first step is to optimize the use of both prostate-specific antigen serum levels and Gleason score.
Clinical genitourinary cancer. 2015 Jun 16 [Epub ahead of print]
Joan Alcover, Xavier Filella
Department of Urology (ICNU), Hospital Clínic, IDIBAPS, Barcelona, Spain. Department of Biochemistry and Molecular Genetics (CDB), Hospital Clínic, IDIBAPS, Barcelona, Spain.